Clinical Trial Update: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial results of palbociclib in patients with advanced or metastatic liposarcoma were posted, detailing outcomes from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liposarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Ibrance (palbociclib) (palbociclib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Liposarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06